Generic Medicine Info
Indications and Dosage
Acute migraine attacks
Adult: 5 or 10 mg as soon as possible after onset, repeat after 2 hours if significant relief is not attained. Max: 20-30 mg per 24 hours.
Special Patient Group
Patients taking concomitant propranolol: Initiate with 5 mg. Max: 10-15 mg daily. Ensure that the 2 drugs are separated by at least 2 hours interval.
Renal Impairment
For mild-moderate impairment, initate with 5 mg. Further dose of 5 mg may be taken after an interval of at least 2 hr. Max: 10 mg/24 hr. Avoid in severe impairment.
Hepatic Impairment
For mild-moderate impairment, initate with 5 mg. Further dose of 5 mg may be taken after an interval of at least 2 hr. Max: 10 mg/24 hr. Avoid in severe impairment.
Tab: May be taken with or without food.
Orally-Disintegrating Tab: May be taken with or without food. Place on the tongue & allow to dissolve; it can then be swallowed w/ the saliva.
History of MI, peripheral vascular disease, transient ishaemic attack, ischaemic heart disease or Prinzmetal's angina; uncontrolled hypertension; basilar or hemiplegic migraine; severe hepatic or renal impairment. Adolescent <18 yr.
Special Precautions
Elderly; mild to moderate hepatic or renal impairment; coronary artery disease; pregnancy, lactation. May cause drowsiness. History of seizures. Ensure an interval of at least 24 hr after stopping an ergotamine compound and starting a serotonin (5-HT1) agonist.
Adverse Reactions
Increased BP, chest pain, palpitation; skin flushing; dyspnoea; nausea, abdominal pain, dry mouth; dizziness, drowsiness, fatigue.
Potentially Fatal: Toxic epidermal necrolysis.
May cause hypertension and CV symptoms. Gastric lavage using activated charcoal may be considered. Monitor ECG and clinical status of the patient.
Drug Interactions
Increased serum concentrations with propranolol. Increased risk of vasospastic reactions when used with ergotamine and methysergide. Concurrent use with SSRIs may increase risk of serotonin syndrome.
Potentially Fatal: Concurrent use with or within 2 wk of stopping MAOI treatment.
Food Interaction
Absorption delayed. Concurrent use with St John's wort may increase risk of adverse reactions.
Description: Rizatriptan is a selective serotonin (5-HT1) agonist in cranial arteries responsible for vasoconstriction and reduction of inflammation associated with antidromic neuronal transmission.
Absorption: Bioavailability: about 40-45%.
Distribution: Protein binding: 14%.
Metabolism: Primarily by monoamine oxidase type A.
Excretion: About 14% of an oral dose is excreted unchanged in the urine. Plasma half-life: about 2-3 hr.
Store at 15-30°C.
MIMS Class
Antimigraine Preparations
Disclaimer: This information is independently developed by MIMS based on Rizatriptan from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in